Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zelquistinel in Major Depressive Disorder
NCT06547489Phase 2Recruiting
- Start
- Feb 2025
- Primary completion
- Sep 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing zelquistinel (GATE-251) with Placebo (2 arms). Primary endpoint: Hamilton Depression Rating Scale-17 at 6 weeks. Started Feb 2025; status: recruiting.
02
Drugs
zelquistinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06547489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547489.